JP2007516202A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516202A5
JP2007516202A5 JP2006518353A JP2006518353A JP2007516202A5 JP 2007516202 A5 JP2007516202 A5 JP 2007516202A5 JP 2006518353 A JP2006518353 A JP 2006518353A JP 2006518353 A JP2006518353 A JP 2006518353A JP 2007516202 A5 JP2007516202 A5 JP 2007516202A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006518353A
Other languages
English (en)
Japanese (ja)
Other versions
JP4653741B2 (ja
JP2007516202A (ja
Filing date
Publication date
Priority claimed from GBGB0315966.2A external-priority patent/GB0315966D0/en
Application filed filed Critical
Publication of JP2007516202A publication Critical patent/JP2007516202A/ja
Publication of JP2007516202A5 publication Critical patent/JP2007516202A5/ja
Application granted granted Critical
Publication of JP4653741B2 publication Critical patent/JP4653741B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006518353A 2003-07-08 2004-07-07 プロテインキナーゼ阻害能のあるチアゾロ−、オキサゾロ−、及びイミダゾロ−キナゾリン化合物 Expired - Fee Related JP4653741B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315966.2A GB0315966D0 (en) 2003-07-08 2003-07-08 Compounds
PCT/GB2004/002935 WO2005005438A1 (en) 2003-07-08 2004-07-07 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases

Publications (3)

Publication Number Publication Date
JP2007516202A JP2007516202A (ja) 2007-06-21
JP2007516202A5 true JP2007516202A5 (enExample) 2011-01-13
JP4653741B2 JP4653741B2 (ja) 2011-03-16

Family

ID=27741793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006518353A Expired - Fee Related JP4653741B2 (ja) 2003-07-08 2004-07-07 プロテインキナーゼ阻害能のあるチアゾロ−、オキサゾロ−、及びイミダゾロ−キナゾリン化合物

Country Status (12)

Country Link
US (1) US7576091B2 (enExample)
EP (1) EP1641805B1 (enExample)
JP (1) JP4653741B2 (enExample)
CN (1) CN100404540C (enExample)
AT (1) ATE455119T1 (enExample)
AU (1) AU2004255924B8 (enExample)
BR (1) BRPI0412363A (enExample)
CA (1) CA2530455A1 (enExample)
DE (1) DE602004025112D1 (enExample)
GB (1) GB0315966D0 (enExample)
IL (1) IL172993A0 (enExample)
WO (1) WO2005005438A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
AU2005293607A1 (en) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102006001161A1 (de) * 2006-01-06 2007-07-12 Qiagen Gmbh Verfahren zum Nachweis von Cytosin-Methylierungen
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
ATE542823T1 (de) * 2006-04-12 2012-02-15 Vertex Pharma 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
DK2212297T3 (da) 2007-10-12 2011-09-05 Ingenium Pharmaceuticals Gmbh Inhibitorer af proteinkinaser
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2009126584A1 (en) * 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2350084B1 (en) * 2008-10-17 2015-06-24 Boehringer Ingelheim International GmbH Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2432671T3 (es) 2009-07-02 2013-12-04 Novartis Ag 2-carboxamida cicloamino ureas útiles como inhibidores de PI3K
CN102834380B (zh) 2010-03-10 2015-04-01 阿斯利康公司 蛋白激酶的抑制剂
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
US20170283445A1 (en) 2016-04-05 2017-10-05 University Of South Carolina Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
CN114213421A (zh) 2017-04-01 2022-03-22 晟科药业(江苏)有限公司 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
ES2923415T3 (es) 2017-08-11 2022-09-27 Shengke Pharmaceuticals Jiangsu Ltd Compuesto de 1H-pirazolo[4,3-H]quinazolina que sirve como inhibidor de proteína quinasa
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN114174301B (zh) * 2019-08-02 2024-03-15 成都赛璟生物医药科技有限公司 1h-[1,2,3]三唑并[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
KR20230057380A (ko) * 2020-08-27 2023-04-28 셍커 파마슈티컬스 (지앙수) 엘티디. 신규한 선택적 flt3 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022165162A1 (en) * 2021-01-29 2022-08-04 Virokyne Therapeutics, Llc Selective cyclin-dependent kinase inhibitors and methods of therapeutic use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024245406A1 (zh) * 2023-06-01 2024-12-05 成都赛璟生物医药科技有限公司 1h-[1,2,3]三唑并[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
HUP0300382A3 (en) * 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
CA2432799C (en) * 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2007516202A5 (enExample)
JP2005261231A5 (enExample)
JP2007514712A5 (enExample)
JP2008512492A5 (enExample)
JP2005194118A5 (enExample)
JP2006257115A5 (enExample)
JP2008512356A5 (enExample)
JP2004168997A5 (enExample)
JP2008512398A5 (enExample)
JP2007505861A5 (enExample)
JP2003305787A5 (enExample)
JP2005120465A5 (enExample)
JP2006063441A5 (enExample)
JP2007119645A5 (enExample)
JP2005095148A5 (enExample)
JP2006045672A5 (enExample)
JP2005290409A5 (enExample)
JP2006101735A5 (enExample)
JP2006523255A5 (enExample)
JP2008525570A5 (enExample)
JP2007525546A5 (enExample)
JP2008524415A5 (enExample)
JP2006273834A5 (enExample)
JP2008525527A5 (enExample)
JP2007001784A5 (enExample)